Skip to content

More bad news on tenofovir/abacavir/3TC

Therapeutic drug monitoring: may predict nelfinavir failure, even when viral load controlled

Better clinical outcomes if HAART started before CD4 cell count falls below 200

Landmark study shows why AZT/3TC/efavirenz now preferred as first-line HIV treatment

Daily nevirapine safe for breastfed infants

Different resistance patterns seen with subtype C HIV in Brazil

Minority can have CD4 rises and no illness for more than 3 years after treatment failure

Fibre-, protein-, calorie-rich diet appears to protect against central fat gain in men

South African drug deal bring $140 a year treatment within reach of African nations